Ng Carey's Form 4 filing
Immix Biopharma, Inc. (IMMX) · filed Dec 20, 2021
- Accession no.
- 0001493152-21-032034
- Filed
- Dec 20, 2021
- Trade date
- Dec 20, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $125.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ng CareyCIK 0001889522 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common Stock | CConversionAcquired | +1,000,221 | $0.85 | +$850,187.85 | 1,000,221 | Indirect | |
| Dec 20, 2021 | Common Stock | PPurchaseAcquired | +25,000 | $5.00 | +$125,000 | 1,025,221 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2021 | Common stock | CConversionDisposed | −1,000,221 | $0.00 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.